News

The year in review: Has economic reform in China gone far enough?

Steven Thai On the 30th November last month, the Chinese currency Renminbi has been approved by the IMF to join the basket of currencies which makes up the Special Drawing Rights (SDR), first created back in 1969. As of 1st October, 2016, RMB will account to 10.92%, which is more than the Japanese Yen and…
Read More

The fall of the Rand

James Zackon On the 9th December South African President Jacob Zuma fired Nhlanha Nene, the Minister of Finance, seemingly out of the blue. The reaction in the financial markets was harsh, as over R170 billion ($10.7 billion) was wiped off the value of South African equities, the Rand falling to record lows of 24.34 against…
Read More

Asia Pacific and Africa expected to provide most opportunities for TMT expansion.

Chihung With the rules of the game in emerging markets changing fast, many of today’s TMT players are fundamentally shifting their focus to the promise of higher growth offered by emerging economies. Choosing where and how to participate in evolving and emerging markets will be key challenges for those active in the TMT space. Last…
Read More

Kalobios Pharmaceuticals experiences complete turnaround

Christophe Brawand Kalobios Pharmaceuticals is a company that strives to improve the lives of patients by developing therapies that treat diseases of high unmet medical need. It specialises in providing cancer patients with customised antibodies. The company was facing financial difficulties at the beginning of the month of November, but has seen its share price…
Read More

Game over for Martin Shkreli and his $750 rip off?

Josh Moss Labelled “the most hated man in America”, he has been criticised by prominent figures such as Hilary Clinton, Bernie Sanders. I even found myself agreeing with Donald Trump for the first time ever when he pointed out that Martin Shkreli “looks like a spoilt brat”. If you have not already read about him…
Read More

Drug development process

Raph Amsili Since the mid-19th century, pharmaceutical industry has had an increasing role in healthcare business. It has become a global phenomenon and governments had had a dual position between supporting research and regulation drug safety and efficacy. For patients, drugs have taken on new medical roles and value. It has become common for people…
Read More

Using its powers for good: Pharmaceutical companies and neglected diseases

Anupurba Roy Pharmaceutical companies have long been hailed as an example of everything that’s wrong with capitalism. Amidst price gouging, aggressive M&A, and cost cutting in R&D- they seem to have forgotten their responsibility towards public health. Though this remains largely the case, it is also important to acknowledge some of the strides they have…
Read More

Shale’s future: Existing but bleak

Nicholas Ogilvie As OPEC announces that it is to forgo an output reduction, the oil market looked out towards a bleak future with persistant low oil prices on the menu. On Friday 4th December, OPEC announced that it would not be changing its stance on output and, put simply by OPEC President Emmanuel Ibe Kachikwu,…
Read More

The Greek Banking Sector

James Zackon Over the past six months the Greek banking sector has lost over 80% of its value. This has come primarily from political uncertainty and capital controls. A bank run by rattled households and companies lead to €37 billion being withdrawn from the banking system – about 18% of the total. Additionally, the high…
Read More

Will the Fed raise interest rates and where should we look for clues?

David Joseph There has been much speculation over what is to be announced on December 16th when the Federal Reserve announces what will happen to the benchmark interest rate. Janet Yellen, the Chair of the Board of Governors for the US’ Federal Reserve System, has been looking to raise benchmark interest rates for some time…
Read More